Key result
ACTN2 frameshift variants drive alpha-actinin-2 aggregation in cell models, suggesting a toxic gain-of-function mechanism.
Why the study?
The clinical significance of many new ACTN2 variants remains unknown, leading to a persistent lack of clear genotype-phenotype correlations in actininopathies.
Observational
Yes
Protein-extending frameshift variants in ACTN2 cause distal myopathy and cardiomyopathy through a toxic gain-of-function mechanism involving protein aggregation.
May guide ACTN2 variant classification in myopathy/cardiomyopathy; leaves open in vivo validation and clinical translation.
Distal myopathies are a group of rare, inherited muscular disorders characterized by progressive loss of muscle fibers that begins in the distal parts of arms and legs. Recently, variants in a new disease gene, ACTN2 , have been shown to cause distal myopathy. ACTN2 , a gene previously only associated with cardiomyopathies, encodes alpha-actinin-2, a protein expressed in both cardiac and skeletal sarcomeres. The primary function of alpha-actinin-2 is to link actin and titin to the sarcomere Z-disk. New ACTN2 variants are continuously discovered, however, the clinical significance of many variants remains unknown. Thus, lack of clear genotype-phenotype correlations in ACTN2 -related diseases, actininopathies, persists. Objective The objective of the study is to characterize the pathomechanisms underlying actininopathies. Methods Functional characterization in C2C12 cell models of several ACTN2 variants is conducted, including frameshift and missense variants associated with dominant actininopathies. We assess the genotype-phenotype correlations of actininopathies using clinical data from several patients carrying these variants. Results The results show that the missense variants associated with a recessive form of actininopathy do not cause detectable alpha-actinin-2 aggregates in the cell model. Conversely, dominant frameshift variants causing a protein extension do produce alpha-actinin-2 aggregates. Interpretation The results suggest that alpha-actinin-2 aggregation is the disease mechanism underlying some dominant actininopathies, and thus we recommend that protein-extending frameshift variants in ACTN2 should be classified as pathogenic. However, this mechanism is likely elicited by only a limited number of variants. Alternative functional characterization methods should be explored to further investigate other molecular mechanisms underlying actininopathies.
No takes yet. Share an insight, caveat, or question.
Ranta‐aho et al. (2024) conducted an observational in Actininopathies (distal myopathy and hypertrophic cardiomyopathy). ACTN2 frameshift variants vs. Wild-type ACTN2 was evaluated on Protein aggregation in cell models. Protein-extending frameshift variants in ACTN2 cause alpha-actinin-2 aggregation in cell models, suggesting a toxic gain-of-function mechanism underlying dominant actininopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: